For patients | Jacobio Pharma

6 Clinical Trials Found

Drug: JAB-21822 Monotherapy

Indication: NSCLC, PDAC, CRC, Other advanced solid tumors

Region: US, Europe

Link: JAB-21822 monotherapy and combination therapy in adult participants with advanced solid tumors harboring KRAS G12C mutation/JAB-21822-1001

Drug: JAB-21822 in combination with Cetuximab

Indication: CRC

Region: US, Europe

Link: JAB-21822 monotherapy and combination therapy in adult participants with advanced solid tumors harboring KRAS G12C mutation/JAB-21822-1001

Drug: JAB-3312 in combination with AMG-510

Indication: NSCLC

Region: US, Europe

Link: JAB-3312-Based Combination Therapies in Adult Patients with Advanced Solid Tumors/JAB-3312-1003

Drug: JAB-8263 Monotherapy

Indication: BRD-NUT, Prostate cancer, Other advanced solid tumors

Region: US

Link: JAB-8263 monotherapy in adult participants with advanced solid tumors/JAB-8263-1001

Drug: JAB-BX102 Monotherapy

Indication: Thyroid cancer, ACC, Other advanced solid tumors

Region: China, US

Link: JAB-BX102 monotherapy in adult participants with advanced solid tumors/JAB-BX102-1001

Drug: JAB-2485 Monotherapy

Indication: TNBC, SCLC, ER+Breast Cancer, Other advanced solid tumors

Region: China, US

Link: JAB-2485 monotherapy in adult participants with advanced solid tumors/JAB-2485-1001